6-S-trityl-6-mercapto-1-hexanol | 100360-57-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 6-S-trityl-6-mercapto-1-hexanol
• 英文别名: 6-(tritylthio)hexan-1-ol；6-tritylthio-1-hexanol；6-triphenylmercaptohexane-1-ol；(S-trityl)-6-mercaptohexan-1-ol；6-Tritylsulfanylhexan-1-ol
• CAS: 100360-57-4
• 化学式: C₂₅H₂₈OS
• 分子量: 376.563
• InChiKey: KIVCMHJKLQHCCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  27
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  45.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-S-trityl-6-mercapto-1-hexanol 在 吡啶 、 silver nitrate 、 三乙胺 作用下， 以 氯仿 为溶剂， 反应 1.5h， 生成 Benzoic acid 6-mercapto-hexyl ester
  参考文献：
  名称：

  De la Torre; Avino; Escarceller, Nucleosides and Nucleotides, 1993, vol. 12, # 9, p. 993 - 1005

  摘要：

  DOI：
• 作为产物：
  描述：

  6-溴正己醇 、 三苯甲硫醇 在 potassium carbonate 作用下， 以 乙醇 、 水 为溶剂， 反应 18.0h， 以100%的产率得到6-S-trityl-6-mercapto-1-hexanol
  参考文献：
  名称：

  Gold nanoparticles protected by fluorinated ligands for 19F MRI

  摘要：

  氟化配体包覆的金纳米颗粒（F-MPCs）在模型实验中表现出适合用于19F磁共振成像的特性。F-MPCs经荧光染料修饰后，被HeLa细胞摄取，并展示了其毒性及其结合疏水分子的能力，这使得它们具有潜在的靶向、递送和成像综合功能。

  DOI：

  10.1039/c3cc44572k

文献信息

• Impact of Distinct Chemical Structures for the Development of a Methamphetamine Vaccine
  作者：Amira Y. Moreno、Alexander V. Mayorov、Kim D. Janda

  DOI：10.1021/ja108807j

  日期：2011.5.4

  (+)-Methamphetamine (METH) use and addiction has grown at alarming rates over the past two decades, while no approved pharmacotherapy exists for its treatment. Immunopharmacotherapy has the potential to offer relief through producing highly specific antibodies that prevent drug penetration across the blood-brain barrier thus decreasing reinforcement of the behavior. Current immunotherapy efforts against methamphetamine have focused on a single hapten structure, namely linker attachment at the aromatic ring of the METH molecule. Hapten design is largely responsible for immune recognition, as it affects presentation of the target antigen and thus the quality of the response. In the current paper we report the systematic generation of a series of haptens designed to target the most stable conformations of methamphetamine as determined by molecular modeling. On the basis of our previous studies with nicotine, we show that introduction of strategic molecular constraint is able to maximize immune recognition of the target structure as evidenced by higher antibody affinity. Vaccination of GIX(+) mice with six unique METH immunoconjugates resulted in high antibody titers for three particularly promising formulations (45-108 mu g/mL, after the second immunization) and high affinity (82, 130, and 169 nM for ME2, MH6, and MH7 hapten-based vaccines, respectively). These findings represent a unique approach to the design of new vaccines against methamphetamine abuse.

  （+）-甲基苯丙胺（METH）的使用和成瘾在过去二十年中以惊人的速度增长，然而目前尚无批准用于治疗的药物疗法。免疫药理学有望通过产生高度特异性的抗体来提供缓解，这些抗体可以阻止药物穿透血脑屏障，从而减少行为的强化。针对甲基苯丙胺的免疫治疗研究一直集中在单一的半抗原结构上，即连接物附着在METH分子的芳香环上。半抗原设计对免疫识别至关重要，因为它影响目标抗原的呈递，从而影响免疫反应的质量。在本文中，我们报告了系统生成一系列半抗原的设计，旨在靶向甲基苯丙胺通过分子建模确定的最稳定构象。基于我们之前对尼古丁的研究，我们表明引入战略性的分子约束能够最大化对目标结构的免疫识别，这一点通过更高的抗体亲和力得到了证明。用六种独特的METH免疫偶联物对GIX(+)小鼠进行免疫接种，结果三种特别有前途的制剂在第二次免疫后产生了高抗体滴度（45-108 μg/mL），并且表现出高亲和力（ME2、MH6和MH7半抗原基疫苗的亲和力分别为82、130和169 nM）。这些发现代表了设计新型甲基苯丙胺滥用疫苗的独特方法。
• Carrier-linked carbamate prodrug linkers
  申请人：Rau Harald

  公开号：US09561285B2

  公开（公告）日：2017-02-07

  The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof, comprising a drug linker conjugate D-L, wherein D being a biologically active moiety containing an aromatic hydroxyl group is conjugated to one or more polymeric carriers via secondary carbamate-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeutically useful half-lives. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments.

  本发明涉及一种前药或其药用可接受的盐，包括药物连接物D-L，其中D是含有芳香羟基的生物活性基团，通过含有二次碳酸酯链的连接物L与一个或多个聚合物载体结合。这种载体连接的前药实现了具有治疗上有用半衰期的药物释放。该发明还涉及包括所述前药的药物组合物及其作为药物的用途。
• [EN] CELL-PENETRATING, GUANIDINIUM-RICH OLIGOPHOSPHOTRIESTERS FOR DRUG AND PROBE DELIVERY<br/>[FR] OLIGOPHOSPHOTRIESTERS RICHES EN GUANIDINIUM À PÉNÉTRATION CELLULAIRE POUR L'ADMINISTRATION DE MÉDICAMENT ET DE SONDE
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2017083637A1

  公开（公告）日：2017-05-18

  Guanidinium-rich oligophosphotriesters transporter compounds and methods of making and using the same are provided. Also provided are pharmaceutical compositions that include the subject transporter compounds, where the transporter can be joined to a cargo of interest, and is formulated with a pharmaceutically acceptable excipient. Formulations may be provided in a unit dose, where the dose provides an amount of the compound effective to afford a desired therapeutic effect. Methods of using the subject transporter compounds to deliver a cargo moiety to a cell are provided, where the method can include contacting a target cell with the transporter compound. The subject methods can be performed in vitro or in vivo.

  提供了富含胍基的寡磷酸三酯转运化合物及其制备和使用方法。还提供了包括所述转运化合物的制药组合物，其中转运体可以与感兴趣的荷物结合，并且与药用可接受的赋形剂配制。可以提供单剂量的配方，其中剂量提供了有效的化合物量，以提供所需的治疗效果。提供了使用所述转运化合物将荷物基团传递至细胞的方法，其中该方法可以包括将转运化合物与目标细胞接触。所述方法可以在体外或体内执行。
• Microwave Assisted Synthesis of<i>S</i>-Trityl and<i>S</i>-Acylmercaptoalkanols, Nucleosides and Their Deprotection
  作者：P. Kumar、K. C. Gupta

  DOI：10.1246/cl.1996.635

  日期：1996.8

  Simple and high yielding methods for the synthesis and deprotection of S-trityl and S-acylhexanols and appropriately protected 2′-deoxynucleosides in solvent and dry media conditions are described which occur under mild conditions using microwave irradiation.

  介绍了在溶剂和干燥介质条件下合成和脱保护 S-三苯甲基和 S-酰基己醇以及适当保护的 2′-脱氧核苷的简单而高产的方法，这些方法是在温和的条件下使用微波辐照进行的。
• PRODRUG COMPRISING A DRUG LINKER CONJUGATE
  申请人：Cleemann Felix

  公开号：US20110053848A1

  公开（公告）日：2011-03-03

  The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L 1 represented by formula (I), wherein the dashed line indicates the attachment to the amine of the biologically active moiety and wherein R 1 , R 1a , R 2 , R 2a , R 3 , R 3a , X, X 1 , X 2 , X 3 have the meaning as indicated in the description and the claims and wherein L 1 is substituted with one to four groups L 2 -Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L 2 is a single chemical bond or a spacer; and Z is a carrier group. The invention also relates to A-L, wherein A is a leaving group, pharmaceutical composition comprising said prodrugs and their use as medicaments.

  本发明涉及一种前药或其药学上可接受的盐，包括药物连接物D-L，其中-D是含有生物活性基团的胺基；而-L是非生物活性的连接基团-L1，由公式（I）表示，其中虚线表示连接到生物活性基团的胺基，其中R1、R1a、R2、R2a、R3、R3a、X、X1、X2、X3在说明书和权利要求中具有所示的含义，而L1用一到四个L2-Z基团取代并可选择进一步取代，前提是在公式（I）中标记为星号的氢未被取代；其中L2是单个化学键或间隔物；而Z是载体基团。本发明还涉及A-L，其中A是离去基团，以及包括所述前药的药物组合物及其作为药物的用途。